Skip to main content

Parental metabolic syndrome epigenetically reprograms offspring hepatic lipid metabolism in mice.

Citation
De Jesus, D. F., et al. “Parental Metabolic Syndrome Epigenetically Reprograms Offspring Hepatic Lipid Metabolism In Mice.”. The Journal Of Clinical Investigation, pp. 2391-2407.
Center Joslin Diabetes Center
Author Dario F De Jesus, Kazuki Orime, Dorota Kaminska, Tomohiko Kimura, Giorgio Basile, Chih-Hao Wang, Larissa Haertle, Renzo Riemens, Natalie K Brown, Jiang Hu, Ville Männistö, Amélia M Silva, Ercument Dirice, Yu-Hua Tseng, Thomas Haaf, Jussi Pihlajamäki, Rohit N Kulkarni
Keywords development, diabetes, Embryonic development, Epigenetics, Hepatology
Abstract

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide. Although gene-environment interactions have been implicated in the etiology of several disorders, the impact of paternal and/or maternal metabolic syndrome on the clinical phenotypes of offspring and the underlying genetic and epigenetic contributors of NAFLD have not been fully explored. To this end, we used the liver-specific insulin receptor knockout (LIRKO) mouse, a unique nondietary model manifesting 3 hallmarks that confer high risk for the development of NAFLD: hyperglycemia, insulin resistance, and dyslipidemia. We report that parental metabolic syndrome epigenetically reprograms members of the TGF-β family, including neuronal regeneration-related protein (NREP) and growth differentiation factor 15 (GDF15). NREP and GDF15 modulate the expression of several genes involved in the regulation of hepatic lipid metabolism. In particular, NREP downregulation increases the protein abundance of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and ATP-citrate lyase (ACLY) in a TGF-β receptor/PI3K/protein kinase B-dependent manner, to regulate hepatic acetyl-CoA and cholesterol synthesis. Reduced hepatic expression of NREP in patients with NAFLD and substantial correlations between low serum NREP levels and the presence of steatosis and nonalcoholic steatohepatitis highlight the clinical translational relevance of our findings in the context of recent preclinical trials implicating ACLY in NAFLD progression.

Year of Publication
2020
Journal
The Journal of clinical investigation
Volume
130
Issue
5
Number of Pages
2391-2407
Date Published
05/2020
ISSN Number
1558-8238
DOI
10.1172/JCI127502
Alternate Journal
J. Clin. Invest.
PMID
32250344
PMCID
PMC7190992
Download citation